Key points are not available for this paper at this time.
The Food Drug Administration (United State of America) approved tirzepatide injection in November 2023 for long -term weight management in adults with obesity or overweight and weight -related conditions like high blood pressure, type 2 diabetes, or high cholesterol. It is a 39 -amino acid synthetic peptide, induces insulin secretion, decreases hyperglycemia, and increases adiponectin levels, suppressing appetite more effectively than long -acting glucagon -like peptide -1 (GLP -1) agonist compounds alone. Clinically meaningful weight reduction observed with trizepatide. Type 2 diabetes (T2D) and obesity are chronic conditions that cannot be cured but can be controlled via therapy, lifestyle modifications, and medical intervention. Drug's weekly dosing schedule improves patient compliance and adherence, making it a promising option for treating obesity and weight reduction in Indian patients. Safety profile is also favours this drugs, gastrointestinal discomfort was the most common adverse event Undoubtedly, the evident superiority of dual incretin agonist tirzepatide over GLP -1 will reignite interest in the therapeutic possibilities of GIP in the context of type 2 diabetes, obesity, and associated comorbidities.
Manoj Kumar Saurabh Amit (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: